| Avtor/Urednik | Pretnar, Jože; Preložnik-Zupan, Irena | |
| Naslov | Zdravljenje akutnih levkemij pri odraslih z alogenično presaditvijo krvotvornih matičnih celic - 14-letne izkušnje | |
| Prevedeni naslov | Allogeneic stem cell transplantation for adult patients with acute leukemia - 14 years experience | |
| Tip | članek | |
| Vir | Zdrav Vestn | |
| Vol. in št. | Letnik 73, št. Suppl 1 | |
| Leto izdaje | 2004 | |
| Obseg | str. I-47-9 | |
| Jezik | slo | |
| Abstrakt | Background. This study was designed to evaluate the impact of various prognostic factors on long-term survival and event free survival after allogeneic hematopoietic stem cell transplantation for patients with acute leukemia. Methods and patients. Between years 1989 and 2002 44 patients with acute leukemia (30 with AML and 24 with ALL) were transplanted. Survival curves using the Kaplan-Meier method were calculated for patients transplanted with two different sources of stem cells - bone marrow and peripheral blood and separately for patients with female donor. Results. Estimated 10 years survival for AML is 43% and 64% for ALL patients which is not statistically different. There are no significant differences in outcome regarding source of stem cells and in donors' gender. Conclusions. To conclude, our results show that neither source of stem cells nor donor's gender has impact on the long-term survival after hematopoietic stem cell transplantation. As published previously patients transplanted beyond the first remission have significantly worse outcome. | |
| Izvleček | Izhodišča. Alogenična presaditev krvotvornih matičnih celic je zelo učinkavit način zdravljenja bolnikov z akutno mieloblastno in limfoblastno levkemijo. V raziskavi smo proučevali vpliv možnih napovednih dejavnikov na uspešnost zdravljenja. Metode. Pri 44 bolnikih z akutno mieloblastno oziroma limfoblastno levkemijo smo v obdobju od leta 1989 do 2002 opravili alogenično presaditev kostnega mozga. Oceno pomena posameznih napovednih dejavnikov smo izračunali s pomočjo krivulje preživetja. Rezultati. Ocenjeno 10-letno preživetje je za akutno mieloblastno levkemijo 43%, za limfoblastno pa 64%. Vir krvotvornih matičnih celic in spol darovalca nista vplivala na izid zdravljenja. Zaključki. Z našo raziskavo nismo uspeli potrditi, da na uspeh presaditve krvotvornih matičnih celic vplivata spol darovalca in vir presajenih krvotvornih matičnih celic. Edini prognostični dejavnik je prisotnost prve remisije bolezni ob presaditvi. | |
| Deskriptorji | LEUKEMIA, MYELOCYTIC, ACUTE LEUKEMIA, LYMPHOCYTIC, ACUTE HEMATOPOIETIC STEM CELL TRANSPLANTATION ADULT SURVIVAL ANALYSIS |